Lansion Biotechnology Co., Ltd.
PrivateLast Round
Series D
Extension
Sep 9, 2022
Total Funding Raised
$34.11M
Company Overview
Lansion Biotechnology Co., Ltd. operates in Healthcare & Life Sciences and is based in Nanjing. Its latest recorded funding round was a Series D Extension round in September 2022.
Lansion Biotechnology Co., Ltd. is a biotechnology company that specializes in the research, development, production, and sale of in-vitro diagnostic (IVD) reagents and devices.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotech Equipment
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Lansion Biotechnology Co., Ltd. Comparables
Compare Lansion Biotechnology Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Chengdu VACURE Biotechnology Co., Ltd. | 88% | |
| Shenzhen Readline Biotechnology Co., Ltd. | 85% | |
| Hangzhou Realy Tech Co., Ltd. | 84% |
For institutional investors. Book with your work email.
Lansion Biotechnology Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D Extension | Sep 9, 2022 | ||||
| Series D Extension | Feb 2, 2022 | ||||
| Series C | Nov 19, 2019 | ||||
| Series A | Apr 28, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Lansion Biotechnology Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CCIC Capital | Series D Extension |
| CICC Capital | Series D Extension |
| MPC | Series C |
| 松禾资本 (Green Pine Capital Partners) | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 9, 2022
$14.3M raised in Series D Extension round.
- Feb 2, 2022
Raised Series D Extension round led by CICC Capital and CCIC Capital.
For institutional investors. Book with your work email.
Lansion Biotechnology Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Lansion Biotechnology Co., Ltd.'s valuation, stock price, and market status.
Is Lansion Biotechnology Co., Ltd. a public or private company?
Lansion Biotechnology Co., Ltd. is a private company.
What is the current stock price of Lansion Biotechnology Co., Ltd.?
Lansion Biotechnology Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Lansion Biotechnology Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Lansion Biotechnology Co., Ltd. worth (valuation)?
Valuation information for Lansion Biotechnology Co., Ltd. is not publicly available.
Can I buy Lansion Biotechnology Co., Ltd. stock?
Lansion Biotechnology Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Lansion Biotechnology Co., Ltd.'s last funding round?
Lansion Biotechnology Co., Ltd.'s most recent funding round was Series D Extension on September 9, 2022.
Who are the main investors in Lansion Biotechnology Co., Ltd.?
Key investors in Lansion Biotechnology Co., Ltd. include CCIC Capital, CICC Capital, MPC, 松禾资本 (Green Pine Capital Partners).
Will Lansion Biotechnology Co., Ltd. IPO soon?
No public IPO plans have been announced for Lansion Biotechnology Co., Ltd..
How can I track Lansion Biotechnology Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Lansion Biotechnology Co., Ltd.'s shares on secondary markets.